©The Author(s) 2025.
World J Gastrointest Oncol. Jul 15, 2025; 17(7): 103337
Published online Jul 15, 2025. doi: 10.4251/wjgo.v17.i7.103337
Published online Jul 15, 2025. doi: 10.4251/wjgo.v17.i7.103337
Figure 3 Available targeted therapeutic options for locally advanced pancreatic ductal adenocarcinoma.
PDAC: Pancreatic ductal adenocarcinoma; BRCA1/2: Breast cancer susceptibility gene 1/2; palb2: Partner and localizer of breast cancer 2; MSI-H: Microsatellite instability high; dMMR: Mismatch repair deficient; NTRK: Neurotrophic receptor tyrosine kinase; nal-IRI: Nanoliposomal irinotecan; 5-FU: 5-fluorouracil; LV: Leucovorin.
- Citation: Hendi M, Zhang B, Mou YP, Cai XJ. Importance of landscape exploration and progress in molecular therapies and precision medicine for pancreatic ductal adenocarcinoma. World J Gastrointest Oncol 2025; 17(7): 103337
- URL: https://www.wjgnet.com/1948-5204/full/v17/i7/103337.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v17.i7.103337